Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 5Recruiting 3Not yet recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 11Recurrence 5Lymphoma, B-Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 3Lymphoma, Mantle-Cell 3Leukemia 3Hematologic Neoplasms 3Oropharyngeal Neoplasms 2Neuroblastoma 2Neoplasms, Plasma Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myeloid 2Hodgkin Disease 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1Pinealoma 1

Interventions

venetoclax 2fludarabine 2fludarabine phosphate 1blinatumomab 1asciminib 1Whole-Body Irradiation 1Idarubicin 1IPI-549 1Filgrastim 1Cytarabine 1Cyclophosphamide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Leukemia, Myeloid × fludarabine × Clear all
NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

NCT07157514 2025-09-10

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Actinium Pharmaceuticals

Phase 2/3 Not yet recruiting
306 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡